Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview

Wu, Changjin; Li, Wentan; Tao, Hongyu; Zhang, Xiyan; Xin, Yu; Song, Ruomeng; Wang, Kaige; Zuo, Ling; Cai, Yuanyi; Wu, Huazhang; Hui, Wen

doi:10.1016/j.critrevonc.2023.104195

Cited by 4 publications

(1 citation statement)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding options for second-line or third-line treatment in these patients, the NCCN Guidelines (2023) ( 9 ) recommend PD-1/PD-L1 inhibitors (Category 2A) such as nivolumab, pembrolizumab, and atezolizumab, or chemotherapeutic agents like docetaxel, pemetrexed, and gemcitabine (Category 2B). However, previous studies ( 10 – 14 ) have demonstrated that economic evaluations of imported PD-1/PD-L1 inhibitors, such as pembrolizumab, nivolumab, and atezolizumab, do not confer a cost-effectiveness advantage. As a domestically developed PD-1/PD-L1 inhibitor, tislelizumab offers a lower price compared to imported counterparts while maintaining comparable efficacy ( 12 ).…”

Section: Introductionmentioning

confidence: 98%

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China

Zhang,

Fan,

Zhang

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundTislelizumab is the first PD-1 inhibitor in China to demonstrate superior efficacy in second-line or third-line treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC). This study aimed to evaluate the cost-effectiveness of tislelizumab compared to docetaxel from a Chinese healthcare system perspective.MethodsA dynamic Markov model was developed to evaluate the cost-effectiveness of tislelizumab in comparison to docetaxel in second or third-line treatment. The efficacy data utilized in the model were derived from the RATIONALE-303 clinical trial, while cost and utility values were obtained from the drug data service platform and published studies. The primary outcomes of the model encompassed quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to validate the robustness of the base case analysis results.ResultsThe tislelizumab group demonstrated a cost increase of CNY 117,473 and a gain of 0.58 QALYs compared to the docetaxel group, resulting in an ICER value of CNY 202,927 per QALY gained.ConclusionThe administration of tislelizumab in patients with advanced or metastatic NSCLC not only extends the progression-free survival (PFS) and overall survival (OS). Moreover, this treatment demonstrates a favorable cost-effectiveness profile across the Chinese population.

show abstract

Section: Introductionmentioning

confidence: 98%

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China

Zhang,

Fan,

Zhang

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

show abstract

Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study

Hu,

Li,

Xie

et al. 2024

Clin Transl Oncol

View full text Add to dashboard Cite

Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis

Maimaitiyiming,

Li,

Cao

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Many studies show that camrelizumab combination therapy can significantly improve progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer (NSCLC). However, the time of camrelizumab to market is short, and there is no systematic evaluation of camrelizumab-based comprehensive treatment of NSCLC. Objectives: To systematically evaluate the efficacy and safety of camrelizumab in comprehensively treating NSCLC. Design: A systematic review and meta-analysis. Data sources and methods: Databases, including PubMed, Web of Science, Embase, and Cochrane, were searched by computer before August 2023 based on Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, and reports on the efficacy and safety of camrelizumab-based treatment for NSCLC were collected, and RevMan 5.4 software was employed for meta-analysis finally. Results: Totally, 5 RCTs, 2 cohort studies, and 12 single-arm studies were included. The meta-analysis results revealed that, compared with the treatment without camrelizumab, the camrelizumab-based combination treatment considerably extended the OS (hazard ratio (HR) = 0.60, 95% confidence interval (CI): (0.44–0.82), p < 0.01), PFS (HR = 0.42, 95% CI: (0.28–0.63), p < 0.01), and event-free survival (EFS) (HR = 0.55, 95% CI: (0.44–0.68), p < 0.01). The median objective response rate in single-arm studies was 41% (95% CI: 28%–53%), and the disease control rate was 84% (95% CI: 78%–89%). Furthermore, in terms of the occurrence of grades 3–5 adverse events, the incidence of neutropenia was lower in the camrelizumab combination group than in the control group, while the incidence of leukopenia and rash was higher than in the combination group, and no significant difference was revealed in the incidence of other adverse events. Among single-arm studies, the incidence of grades 3–5 adverse events did not exceed 10%. Conclusion: Treatment combined with camrelizumab can effectively prolong OS, PFS, and EFS in NSCLC patients with good safety, camrelizumab combined with chemotherapy is an effective treatment option for NSCLC patients.

show abstract

Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview

Cited by 4 publications

References 79 publications

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China

Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study

Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About